Current therapies for advanced melanoma typically include BRAF (BRaf proto-oncogene, serine/threonine kinase) and MEK (mitogen-activated protein kinase)-targeted agents and/or checkpoint-targeted immunotherapy (ipilimumab, pembrolizumab, and nivolumab). Here, BRAF is linked to melanoma.